Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Owen Kramer

MOHS-Micrographic Surgery Elmhurst, IL Medical Doctor

NPI 1477086874 CMS profile 4220106

103 N Haven Rd Ste 7, Elmhurst, IL 60126

Open in the dashboard

General payments

$10,409

473 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Owen Kramer of Elmhurst, IL is reported in the CMS Open Payments database as having received $10,409 across 473 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,329 161
2024 General $2,696 113
2023 General $1,955 91
2022 General $1,232 56
2021 General $405 23
2020 General $328 14
2019 General $465 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Owen Kramer
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Owen Kramer were reported at $3,329. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Owen Kramer MOHS-Micrographic Surgery median Middle half National median
2019 $465 $316 $106–$785 $163
2020 $328 $162 $68–$412 $114
2021 $405 $243 $87–$654 $132
2022 $1,232 $300 $102–$887 $149
2023 $1,955 $364 $125–$1,010 $160
2024 $2,696 $445 $142–$1,108 $164
2025 $3,329 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,984 99 payments
  2. Lilly USA, LLC $1,282 57 payments
  3. Regeneron Healthcare Solutions, Inc. $1,184 33 payments
  4. Sun Pharmaceutical Industries Inc. $882 41 payments
  5. Janssen Biotech, Inc. $860 36 payments
  6. Genzyme Corporation $647 16 payments
  7. Galderma Laboratories, L.P. $480 37 payments
  8. Pfizer Inc. $436 27 payments
  9. Arcutis Biotherapeutics, Inc. $399 26 payments
  10. E.R. Squibb & Sons, L.L.C. $372 23 payments
  11. Other $1,884 78 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,108 469 payments
  2. Education $285 3 payments
  3. Travel and Lodging $16 1 payment
Products named General payments · program years 2019–2025
  1. TALTZ $1,097 53 payments
  2. SKYRIZI $934 45 payments
  3. TREMFYA $860 36 payments
  4. DUPIXENT Inflammation And Immunology $686 17 payments
  5. DUPIXENT Immunology $664 17 payments
  6. ILUMYA $610 31 payments
  7. EBGLYSS $537 22 payments
  8. RINVOQ $522 28 payments
  9. HUMIRA $500 22 payments
  10. CIBINQO $436 27 payments
  11. Other $6,029 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

702

Median for Dermatology: 534

Drug cost

$166,897

Median for Dermatology: $67,151

Branded share of claims

6.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 15 $101,661
Dupixent Pen Dupilumab Brand 13 $46,674
Clobetasol Propionate Generic 114 $5,322
Ketoconazole Generic 130 $2,185
Tacrolimus Generic 21 $1,957
Fluocinonide Generic 45 $1,677
Metronidazole Generic 34 $1,658
Doxycycline Monohydrate Generic 62 $1,651
Triamcinolone Acetonide Generic 110 $1,074
Fluorouracil Generic 12 $906

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$235,932

Of which drugs: $12,025

Medicare patients

660

Average age 76

Services billed

5,034

299 women, 361 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 47%
Ischemic heart disease 28%
Diabetes 24%
Chronic kidney disease 20%
Atrial fibrillation 17%
Cancer 17%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $338
$338 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $156
  • GENZYME CORPORATION $135
$290 13 —
TREMFYA
  • Janssen Biotech, Inc. $277
$277 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $211
$211 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $197
$197 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record